← Leaderboards
Lawrence Corey
Fred Hutchinson Cancer Center
$859,232,520
Attributed
$1,535,777,764
Total exposure
23
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $460.3M · FY2005–25$500M$375M$250M$125M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,577,638,265 · 25
By mechanism
UM1$1,142,518,571 · 1
U01$312,186,553 · 3
S10$47,702,580 · 3
P30$42,583,880 · 5
P01$22,768,665 · 8
R01$6,294,303 · 3
Top collaborators
- Glenda E Gray27 shared
- Dan H. Barouch19 shared
- Georgia D Tomaras19 shared
- Scott M Hammer7 shared
- Jia Zhu5 shared
Most similar at Fred Hutchinson Cancer Center
Same institution · by research overlap
- Peter B. Gilbert$223,972,501
- Yunda Huang$75,372,842
- Holly Janes$70,932,400
- Margaret Juliana McElrath$601,692,649
- Georgia D Tomaras$127,423,185
Others in their field
Top investigators on “Leadership”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$556,543,150
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Judith S. Currier · University Of California Los Angeles$453,081,663
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$389,598,243
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$351,419,848
Research focus
LeadershipAreaProgramsFundingClinical TrialsClinical ResearchPersonsLaboratoriesGrantSiteCancer Center Support GrantPlayResourcesHiv InfectionsPreventionImmune ResponseTransmission ProcessVaccinesMemberInfectionDesignT-LymphocyteCatchment AreaEnrollment
Grant awards (174)
HIV Vaccines Clinical Trials Network Leadership and Operations Center$30,396,659
UM1 · FY2025 · AI · contact PI
HIV Vaccines Clinical Trials Network Leadership and Operations Center$21,949,062
UM1 · FY2024 · AI · contact PI
LOC: HIV Vaccine Trials Network$2,797,660
UM1 · FY2024 · AI · contact PI
HIV Vaccines Clinical Trials Network Leadership and Operations Center$38,851,667
UM1 · FY2023 · AI · contact PI
CoVPN 3008 - Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern$19,404,520
UM1 · FY2023 · AI · contact PI
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older$2,683,830
UM1 · FY2023 · AI · contact PI
PPE Request$1,438,731
S10 · FY2023 · AI · contact PI
CoVPN 3001$305,278
UM1 · FY2023 · AI · contact PI
CoVPN 3008 - Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern$55,953,346
UM1 · FY2022 · AI · contact PI
HIV Vaccines Clinical Trials Network Leadership and Operations Center$34,194,667
UM1 · FY2022 · AI · contact PI
HIV Vaccines Clinical Trials Network Leadership and Operations Center$17,943,267
UM1 · FY2022 · AI · contact PI
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older$9,754,127
UM1 · FY2022 · AI · contact PI
HIV Vaccines Clinical Trials Network Leadership and Operations Center$6,272,147
UM1 · FY2022 · AI · contact PI
CoVPN 3004 - A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine LOC$5,663,427
UM1 · FY2022 · AI · contact PI
CoVPN LOC Cross-Protocol Infrastructure Supplement for GY15 and GY16$5,323,993
UM1 · FY2022 · AI · contact PI
CoVPN 3001 GY16 PostMerger LOC$3,879,990
UM1 · FY2022 · AI · contact PI
Harnessing Tissue Resident Memory T Cells for Immunotherapy of Herpes Virus Infections$667,493
R01 · FY2022 · AI · contact PI
CoVPN 3502 A Phase 3, Randomized, Double LOC GY16$293,963
UM1 · FY2022 · AI · contact PI
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older$61,429,109
UM1 · FY2021 · AI · contact PI
HIV Vaccines Clinical Trials Network Leadership and Operations Center$43,124,622
UM1 · FY2021 · AI · contact PI
HIV Vaccines Clinical Trials Network Leadership and Operations Center$40,320,056
UM1 · FY2021 · AI · contact PI
Personal Protective Equipment for Resources for COVID-19 Related Vaccine and Treatment Clinical Trials and Clinical Studies$21,360,749
S10 · FY2021 · AI · contact PI
Harnessing Tissue Resident Memory T Cells for Immunotherapy of Herpes Virus Infections$564,908
R01 · FY2021 · AI · contact PI
Harnessing Tissue Resident Memory T Cells for Immunotherapy of Herpes Virus Infections$102,585
R01 · FY2021 · AI · contact PI
HVTN 405/HPTN 1901 Characterizing SARS-CoV-2-specific immunity in convalescent individuals$393,953,893
UM1 · FY2020 · AI · contact PI
LOC: HIV Vaccine Trials Network$40,823,093
UM1 · FY2020 · AI · contact PI
Personal Protective Equipment for Resources for COVID-19 Related Vaccine and Treatment Clinical Trials and Clinical Studies$24,903,100
S10 · FY2020 · AI · contact PI
Harnessing Tissue Resident Memory T Cells for Immunotherapy of Herpes Virus Infections$667,493
R01 · FY2020 · AI · contact PI
LOC: HIV Vaccine Trials Network$36,148,992
UM1 · FY2019 · AI · contact PI
Developmental Funds$1,884,315
P30 · FY2019 · CA · contact PI
Administration$1,252,772
P30 · FY2019 · CA · contact PI
Harnessing Tissue Resident Memory T Cells for Immunotherapy of Herpes Virus Infections$667,493
R01 · FY2019 · AI · contact PI
Administration$201,108
P30 · FY2019 · CA · contact PI
Administration$199,999
P30 · FY2019 · CA · contact PI
Planning and Evaluation$50,886
P30 · FY2019 · CA · contact PI
Administration$9,136
P30 · FY2019 · CA · contact PI
Planning and Evaluation$9,136
P30 · FY2019 · CA · contact PI
Developmental Funds$9,135
P30 · FY2019 · CA · contact PI
Planning and Evaluation$7,408
P30 · FY2019 · CA · contact PI
Developmental Funds$7,408
P30 · FY2019 · CA · contact PI
Planning and Evaluation$3,703
P30 · FY2019 · CA · contact PI
Administration$3,703
P30 · FY2019 · CA · contact PI
Developmental Funds$3,703
P30 · FY2019 · CA · contact PI
Developmental Funds$2,890
P30 · FY2019 · CA · contact PI
Administration$2,890
P30 · FY2019 · CA · contact PI
Planning and Evaluation$2,890
P30 · FY2019 · CA · contact PI
LOC: HIV Vaccine Trials Network$55,377,361
UM1 · FY2018 · AI · contact PI
Developmental Funds$1,884,317
P30 · FY2018 · CA · contact PI
Administration$1,252,774
P30 · FY2018 · CA · contact PI
Harnessing Tissue Resident Memory T Cells for Immunotherapy of Herpes Virus Infections$686,493
R01 · FY2018 · AI · contact PI
Planning and Evaluation$50,888
P30 · FY2018 · CA · contact PI
Administration$9,136
P30 · FY2018 · CA · contact PI
Planning and Evaluation$9,136
P30 · FY2018 · CA · contact PI
Developmental Funds$9,135
P30 · FY2018 · CA · contact PI
Planning and Evaluation$8,334
P30 · FY2018 · CA · contact PI
Developmental Funds$8,334
P30 · FY2018 · CA · contact PI
Administration$8,334
P30 · FY2018 · CA · contact PI
Developmental Funds$7,408
P30 · FY2018 · CA · contact PI
Planning and Evaluation$7,408
P30 · FY2018 · CA · contact PI
Administration$7,408
P30 · FY2018 · CA · contact PI
Planning and Evaluation$2,890
P30 · FY2018 · CA · contact PI
Developmental Funds$2,890
P30 · FY2018 · CA · contact PI
Administration$2,890
P30 · FY2018 · CA · contact PI
Developmental Funds$1,235
P30 · FY2018 · CA · contact PI
Administration$1,235
P30 · FY2018 · CA · contact PI
Planning and Evaluation$1,235
P30 · FY2018 · CA · contact PI
LOC: HIV Vaccine Trials Network$50,375,222
UM1 · FY2017 · AI · contact PI
Developmental Funds$1,701,922
P30 · FY2017 · CA · contact PI
Administration$1,145,654
P30 · FY2017 · CA · contact PI
Planning and Evaluation$87,021
P30 · FY2017 · CA · contact PI
LOC: HIV Vaccine Trials Network$30,221,723
UM1 · FY2016 · AI · contact PI
Developmental Funds$1,884,695
P30 · FY2016 · CA · contact PI
Administration$1,253,023
P30 · FY2016 · CA · contact PI
Cytotoxic T-Cell Responses to HSV in HIV-Infected Persons$437,105
R01 · FY2016 · AI · contact PI
Planning and Evaluation$50,893
P30 · FY2016 · CA · contact PI
LOC: HIV Vaccine Trials Network$17,738,847
UM1 · FY2015 · AI · contact PI
Developmental Funds$1,899,206
P30 · FY2015 · CA · contact PI
Administration$1,287,235
P30 · FY2015 · CA · contact PI
Cytotoxic T-Cell Responses to HSV in HIV-Infected Persons$437,133
R01 · FY2015 · AI · contact PI
Planning and Evaluation$52,283
P30 · FY2015 · CA · contact PI
LOC: HIV Vaccine Trials Network$36,427,285
UM1 · FY2014 · AI · contact PI
Cytotoxic T-Cell Responses to HSV in HIV-Infected Persons$437,156
R01 · FY2014 · AI · contact PI
Specimen Repository and Virology$116,823
P01 · FY2014 · AI · contact PI
Leadership Group for a Global HIV Vaccine Clinical Trials Network$11,269,896
UM1 · FY2013 · AI · contact PI
Cytotoxic T-Cell Responses to HSV in HIV-Infected Persons$409,622
R01 · FY2013 · AI · contact PI
Specimen Repository and Virology$97,621
P01 · FY2013 · AI · contact PI
Leadership Group for a Global HIV Vaccine Clinical Trials Network$32,353,045
UM1 · FY2012 · AI · contact PI
Cancer Center Support Grant (Comprehensive)$11,373,047
P30 · FY2012 · CA · contact PI
Cytotoxic T-Cell Responses to HSV in HIV-Infected Persons$453,463
R01 · FY2012 · AI · contact PI
Laboratory Core$322,667
P01 · FY2012 · AI · contact PI
Administrative Core$285,594
P01 · FY2012 · AI · contact PI
Mechanisms of Reactivation and Clearance of Mucosal HSV Infection$273,587
P01 · FY2012 · AI · contact PI
Cancer Center Support Grant (Comprehensive)$211,800
P30 · FY2012 · CA · contact PI
Cancer Center Support Grant (Comprehensive)$139,999
P30 · FY2012 · CA · contact PI
Cancer Center Support Grant (Comprehensive)$116,988
P30 · FY2012 · CA · contact PI
Specimen Repository and Virology$113,330
P01 · FY2012 · AI · contact PI
Cancer Center Support Grant (Comprehensive)$74,876
P30 · FY2012 · CA · contact PI
Cancer Center Support Grant (Comprehensive)$50,000
P30 · FY2012 · CA · contact PI
Leadership Group for a Global HIV Vaccine Clinical Trials Network$37,287,824
UM1 · FY2011 · AI · contact PI
Cancer Center Support Grant (Comprehensive)$10,429,029
P30 · FY2011 · CA · contact PI
Cancer Center Support Grant (Comprehensive)$704,000
P30 · FY2011 · CA · contact PI
Cytotoxic T-Cell Responses to HSV: HIV-Infected Persons$388,659
R37 · FY2011 · AI · contact PI
Laboratory Core$354,993
P01 · FY2011 · AI · contact PI
Mechanisms of Reactivation and Clearance of Mucosal HSV Infection$327,902
P01 · FY2011 · AI · contact PI
Cancer Center Support Grant (Comprehensive)$211,800
P30 · FY2011 · CA · contact PI
Specimen Repository and Virology$185,220
P01 · FY2011 · AI · contact PI
Administrative Core$169,539
P01 · FY2011 · AI · contact PI
Cancer Center Support Grant (Comprehensive)$139,269
P30 · FY2011 · CA · contact PI
Cancer Center Support Grant (Comprehensive)$116,988
P30 · FY2011 · CA · contact PI
Cancer Center Support Grant (Comprehensive)$75,000
P30 · FY2011 · CA · contact PI
Leadership Group for a Global HIV Vaccine Clinical Trials Network$21,443,783
U01 · FY2010 · AI · contact PI
Leadership Group for a Global HIV Vaccine Clinical Trials Network$2,000,000
U01 · FY2010 · AI · contact PI
Laboratory Core$652,739
P01 · FY2010 · AI · contact PI
Mechanisms of Reactivation and Clearance of Mucosal HSV Infection$604,504
P01 · FY2010 · AI · contact PI
Cytotoxic T-Cell Responses to HSV: HIV-Infected Persons$320,011
R37 · FY2010 · AI · contact PI
Specimen Repository and Virology$196,226
P01 · FY2010 · AI · contact PI
Administrative Core$98,834
P01 · FY2010 · AI · contact PI
Cytotoxic T-Cell Responses to HSV: HIV-Infected Persons$54,810
R37 · FY2010 · AI · contact PI
Leadership Group for a Global HIV Vaccine Clinical Trials Network$34,168,787
U01 · FY2009 · AI · contact PI
Clinical Epidemiology and Pathogenesis of Asymptomatic HSV$2,007,507
P01 · FY2009 · AI · contact PI
Cancer Center Support Grant (Comprehensive)$1,586,953
P30 · FY2009 · CA · contact PI
Cancer Center Support Grant (Comprehensive)$749,121
P30 · FY2009 · CA · contact PI
Laboratory Core$626,678
P01 · FY2009 · AI · contact PI
Mechanisms of Reactivation and Clearance of Mucosal HSV Infection$581,231
P01 · FY2009 · AI · contact PI
Cytotoxic T-Cell Responses to HSV: HIV-Infected Persons$446,416
R37 · FY2009 · AI · contact PI
Cancer Center Support Grant (Comprehensive)$138,561
P30 · FY2009 · CA · contact PI
Administrative Core$99,724
P01 · FY2009 · AI · contact PI
Leadership Group for a Global HIV Vaccine Clinical Trials Network$26,907,846
U01 · FY2008 · AI · contact PI
Leadership Group for a Global HIV Vaccine Clinical Trials Network$2,838,119
U01 · FY2008 · AI · contact PI
Clinical Epidemiology and Pathogenesis of Asymptomatic HSV$1,959,998
P01 · FY2008 · AI · contact PI
Laboratory Core$655,392
P01 · FY2008 · AI · contact PI
Mechanisms of Reactivation and Clearance of Mucosal HSV Infection$517,501
P01 · FY2008 · AI · contact PI
Cytotoxic T-Cell Responses to HSV: HIV-Infected Persons$326,607
R37 · FY2008 · AI · contact PI
Administrative Core$99,548
P01 · FY2008 · AI · contact PI
Leadership Group for a Global HIV Vaccine Clinical Trials Network$41,690,531
U01 · FY2007 · AI · contact PI
Clinical Epidemiology & Pathogenesis of Asymptomatic HSV$1,617,478
P01 · FY2007 · AI · contact PI
Cytotoxic T-Cell Responses to HSV: HIV-Infected Persons$352,823
R37 · FY2007 · AI · contact PI
Leadership Group for a Global HIV Vaccine Clinical Trials Network$52,490,835
U01 · FY2006 · AI · contact PI
Clinical Epidemiology & Pathogenesis of Asymptomatic HSV$1,618,410
P01 · FY2006 · AI · contact PI
Cytotoxic T-Cell Responses to HSV: HIV-Infected Persons$319,906
R37 · FY2006 · AI · contact PI
HIV VACCINE TRAILS NETWORK LEADERSHIP GROUP$26,001,414
U01 · FY2005 · AI
HIV VACCINE TRAILS NETWORK LEADERSHIP GROUP$5,400,000
U01 · FY2005 · AI
Clinical Epidemiology &Pathogenesis of Asymptomatic HSV$1,628,047
P01 · FY2005 · AI
Cytotoxic T-Cell Responses to HSV: HIV-Infected Persons$328,313
R37 · FY2005 · AI
HIV VACCINE TRAILS NETWORK LEADERSHIP GROUP$21,662,323
U01 · FY2004 · AI
Clinical Epidemiology &Pathogenesis of Asymptomatic HSV$1,648,154
P01 · FY2004 · AI
Cytotoxic T-Cell Responses to HSV: HIV-Infected Persons$328,994
R37 · FY2004 · AI
HIV VACCINE TRAILS NETWORK LEADERSHIP GROUP$25,867,621
U01 · FY2003 · AI
Clinical Epidemiology &Pathogenesis of Asymptomatic HSV$1,607,124
P01 · FY2003 · AI
IMMUNOLOGY AND MOLECULAR VIROLOGY OF ACUTE HIV INFECTION$443,953
U01 · FY2003 · AI
Cytotoxic T-Cell Responses to HSV: HIV-Infected Persons$332,174
R37 · FY2003 · AI
Oral-Pharyngeal HHV-8 Infection$273,600
R01 · FY2003 · DE
HIV VACCINE TRAILS NETWORK LEADERSHIP GROUP$23,761,072
U01 · FY2002 · AI
CLINICAL EPIDEMIOLOGY &PATHOGENESIS OF ASYMPTOMATIC HSV$1,268,198
P01 · FY2002 · AI
IMMUNOLOGY AND MOLECULAR VIROLOGY OF ACUTE HIV INFECTION$1,167,948
U01 · FY2002 · AI
Cytotoxic T-Cell Responses to HSV: HIV-Infected Persons$346,000
R37 · FY2002 · AI
HSV INFECTION IN HIV INFECTED INDIVIDUALS$228,401
P01 · FY2002 · AI
CORE--CLINICAL RESEARCH$0
P30 · FY2002 · AI
INFECTIOUS COMPLICATIONS$0
P01 · FY2002 · CA
HIV VACCINE TRAILS NETWORK LEADERSHIP GROUP$18,073,186
U01 · FY2001 · AI
IMMUNOLOGY AND MOLECULAR VIROLOGY OF ACUTE HIV INFECTION$2,246,363
U01 · FY2001 · AI
CLINICAL EPIDEMIOLOGY &PATHOGENESIS OF ASYMPTOMATIC HSV$1,234,634
P01 · FY2001 · AI
CYTOTOXIC T CELL RESPONSES TO HSV IN HIV INFECTION$248,499
R01 · FY2001 · AI
CORE--CLINICAL RESEARCH$0
P30 · FY2001 · AI
CORE--VIROLOGY$0
P01 · FY2001 · AI
HSV INFECTION IN HIV INFECTED INDIVIDUALS$0
P01 · FY2001 · AI
HIV VACCINE TRAILS NETWORK LEADERSHIP GROUP$3,920,639
U01 · FY2000 · AI
IMMUNOLOGY AND MOLECULAR VIROLOGY OF ACUTE HIV INFECTION$2,102,133
U01 · FY2000 · AI
CLINICAL EPIDEMIOLOGY &PATHOGENESIS OF ASYMPTOMATIC HSV$1,153,520
P01 · FY2000 · AI
CORE--VIROLOGY$251,290
P01 · FY2000 · AI
CYTOTOXIC T CELL RESPONSES TO HSV IN HIV INFECTION$241,260
R01 · FY2000 · AI
CORE--CLINICAL RESEARCH$178,448
P30 · FY2000 · AI
HSV INFECTION IN HIV INFECTED INDIVIDUALS$166,251
P01 · FY2000 · AI
AIDS VACCINE EVALUATION UNITS$39,000
N01 · FY2000 · AI